Mendus AB (OSTO:IMMU) Valuation Rank


OSTO:IMMU Mendus AB OSTO:IMMU
29 GF Score
Price kr6.11
! 2 Warning Signs
View Full Analysis

What is Mendus AB Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Mendus AB Valuation Rank Related Terms

OSTO:IMMU
29GF Score
Mendus AB OSTO:IMMU
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mendus AB Business Description

Other Exchanges 1YG0:Germany
Address Vastra Tradgardsgatan 15, Stockholm, SWE, 11153
Mendus AB is a clinical-level biopharmaceutical company based on the company's allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. Its operations consist of research and development for pharmaceuticals. The company's Pipeline includes: Vididencel, and Ilixadencel.
29GF Score

Get the complete analysis for OSTO:IMMU

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr6.11
Price